Case Study: Rheumatoid Arthritis (RA) – Pharmacotherapy A 45-year-old woman presents to the rheumatology clinic with a 6-month history of symmetrical pain, swelling, and stiffness of the small joints of both hands and wrists. She reports that the morning stiffness lasts approximately 2 hours and improves slightly with movement. She also complains of fatigue and difficulty performing household activities. On examination, the metacarpophalangeal and proximal interphalangeal joints are tender and swollen. Laboratory investigations show ESR 58 mm/hr, CRP 24 mg/L, positive rheumatoid factor and anti-CCP antibodies. Her CBC, liver function tests, and renal function are within normal limits. X-ray of the hands shows early joint-space narrowing without major erosions. She has no history of tuberculosis, hepatitis, peptic ulcer disease, or renal disease. The physician diagnoses early active rheumatoid arthritis and initiates methotrexate 15 mg once weekly with folic acid supplementation, with a short course of NSAID for symptomatic relief. The patient is advised that methotrexate is a long-term disease-modifying treatment and requires regular monitoring. Questions for Pharmacotherapy Discussion What is the most appropriate first-line pharmacological treatment for this patient? Why? What is the mechanism of action of methotrexate in rheumatoid arthritis? Why is folic acid prescribed along with methotrexate? What is the usual dosing schedule of methotrexate in RA, and why should it not be taken daily? What are the important adverse effects of methotrexate that should be explained to the patient? Which baseline investigations should be performed before initiating methotrexate? What laboratory parameters should be regularly monitored during methotrexate therapy? What is the role of NSAIDs in this patient's treatment? Do they prevent disease progression? If disease activity remains high after an adequate trial of methotrexate, what pharmacotherapeutic options can be considered? Compare conventional synthetic DMARDs, biologic DMARDs, and targeted synthetic DMARDs used in RA. What precautions should be taken regarding vaccination and infections in a patient receiving DMARD therapy? What important patient counselling points should the pharmacist provide to this patient? If the patient develops significant hepatotoxicity or bone-marrow suppression during treatment, how should methotrexate therapy be managed? Why are glucocorticoids generally used for short-term bridging therapy rather than as long-term monotherapy in RA? Design a pharmacotherapy plan for the next 3–6 months, including treatment, monitoring, safety assessment, and evaluation of therapeutic response

Reading File

Initial treatment strategy
- First-line methotrexate-based treatment
- Treat-to-target goals and role of short-term symptom control
Methotrexate pharmacology
- Mechanism in RA
- Weekly dosing, folic acid, adverse effects, interactions, and toxicity management
Baseline assessment and monitoring
- Pretreatment screening
- CBC, liver, renal monitoring and thresholds for withholding treatment
Other RA drug classes
- NSAIDs and glucocorticoid bridging
- Conventional synthetic, biologic, and targeted synthetic DMARDs
- Options after inadequate methotrexate response
Safety, infection, vaccination, and counselling
- Infection precautions and vaccination timing
- Pregnancy, alcohol, adherence, and red-flag symptoms
A practical 3-6 month pharmacotherapy plan
- Dose escalation or adjustment
- Monitoring schedule and disease activity assessment
- When to add or switch therapy

This presentation is typical of early, active, seropositive RA with poor prognostic features, including anti-CCP positivity and elevated inflammatory markers. Methotrexate is generally the anchor first-line conventional DMARD when there is no contraindication. Its purpose is to suppress inflammation, prevent structural joint damage, and preserve function. NSAIDs can lessen pain and stiffness but do not alter the disease course.

Care should follow a treat-to-target approach: assess disease activity frequently, optimize methotrexate with folic acid and safety monitoring, and escalate treatment if the target of remission or low disease activity is not reached. Screening for infection risks, appropriate vaccinations, and clear patient counselling are integral to safe DMARD treatment.

Which area should I cover in detail first?

answer the questions

Reading File

Finding Sources

Searching PubMed

"rheumatoid arthritis"[MeSH Terms] AND "methotrexate"[MeSH Terms]

Searching the Web

2025 EULAR rheumatoid arthritis treatment recommendations methotrexate vaccination monitoring

Finding Sources

Reading Web Page

https://ard.eular.org/article/S0003-4967(25)00818-0/fulltext

Searching PubMed

"rheumatoid arthritis"[MeSH Terms] AND vaccination

Reading File

1. Most appropriate first-line pharmacological treatment and rationale

Methotrexate (MTX) once weekly plus folic acid is the preferred first-line disease-modifying antirheumatic drug (DMARD) for this patient.

She has early, active, seropositive RA with elevated ESR/CRP, anti-CCP positivity, functional limitation, and early radiographic joint-space narrowing. These features support prompt initiation of a DMARD to prevent irreversible joint damage. MTX is the “anchor” conventional synthetic DMARD because it has good efficacy, long-term experience, acceptable safety with monitoring, and can later be combined with other DMARDs if needed.

Her prescribed MTX 15 mg once weekly is appropriate. It may be optimized to 20-25 mg once weekly if tolerated and disease activity remains above target. Current EULAR guidance continues to recommend starting a DMARD as soon as RA is diagnosed, aiming for sustained remission or low disease activity, with reassessment at 1-3-month intervals (EULAR RA recommendations).

A short course of an NSAID is reasonable for pain and stiffness. A short glucocorticoid course may be considered if symptoms are severe while waiting for MTX to work, but it should be tapered promptly.

2. Mechanism of action of methotrexate in RA

At the low weekly doses used in RA, MTX acts mainly as an anti-inflammatory and immunomodulatory drug, rather than as a cytotoxic anticancer drug.

Key actions:

MTX is a folate analogue that inhibits enzymes involved in folate-dependent purine and pyrimidine synthesis.
Intracellular MTX polyglutamates inhibit aminoimidazole carboxamide ribonucleotide transformylase.
This increases extracellular adenosine, an anti-inflammatory mediator.
Adenosine reduces activation and inflammatory activity of neutrophils, macrophages, lymphocytes, and synovial cells.
MTX reduces pro-inflammatory cytokine activity and limits synovial inflammation, thereby slowing cartilage and bone damage.

This adenosine-mediated anti-inflammatory activity is particularly important at RA doses. Goldman-Cecil Medicine describes inhibition of dihydrofolate reductase and increased intracellular adenosine as central mechanisms in low-dose MTX therapy. Goldman-Cecil Medicine, p. 2810.

3. Why folic acid is given with methotrexate

MTX interferes with folate metabolism. Folic acid reduces toxicity without materially reducing MTX efficacy at standard supplementation doses.

It reduces the risk of:

Nausea and vomiting
Stomatitis and mouth ulcers
Gastrointestinal intolerance
Elevated liver enzymes
Some hematologic toxicity

Common regimens include:

Folic acid 1 mg orally daily, often omitted on the MTX day, or
Folic acid 5 mg once weekly, usually on the day after MTX.

Folic or folinic acid supplementation reduces nausea, oral ulceration, and possibly liver-enzyme abnormalities without reducing MTX benefit. Rheumatology, 2-Volume Set, p. 908-912.

4. Usual methotrexate dosing schedule and why it must not be taken daily

Usual RA schedule

Starting dose: 10-15 mg orally once weekly
Escalation: increase by about 2.5-5 mg weekly every 2-4 weeks, if tolerated and disease remains active
Typical optimized dose: 20-25 mg once weekly
Maximum commonly used dose: 25 mg once weekly
Administration: oral tablets or subcutaneous injection

If oral treatment causes nausea, poor absorption, or inadequate response at 15 mg or more weekly, switching to subcutaneous MTX is often helpful.

Why it must never be taken daily

MTX for RA is a weekly drug, not a daily drug. Daily administration can cause severe cumulative toxicity, including:

Profound pancytopenia
Severe mucositis and gastrointestinal ulceration
Sepsis
Acute kidney injury
Potentially fatal toxicity

The patient should be asked to select and document one fixed “MTX day” each week, for example, every Monday. Prescriptions, labels, and medication charts should clearly state: “Take once weekly only.”

5. Important adverse effects to explain

Common or relatively common

Nausea, vomiting, dyspepsia, abdominal discomfort
Fatigue or malaise after the weekly dose
Mouth ulcers or sore throat
Mild hair thinning
Headache
Elevated transaminases

Serious adverse effects

Bone-marrow suppression: leukopenia, neutropenia, thrombocytopenia, anemia, pancytopenia
Hepatotoxicity: persistent transaminitis, fibrosis, rarely cirrhosis
Pulmonary toxicity: MTX pneumonitis, usually presenting with new dry cough, dyspnea, fever, or hypoxia
Increased susceptibility to infection
Severe mucositis
Renal accumulation and toxicity if renal function declines
Teratogenicity, miscarriage, and fetal harm

The patient should seek urgent medical advice for fever, infection symptoms, unusual bruising or bleeding, severe sore throat, mouth ulcers, black stools, persistent vomiting, jaundice, dark urine, or new cough or breathlessness.

MTX is associated with liver toxicity, marrow suppression, and infection risk. Goldman-Cecil Medicine, p. 2816.

6. Baseline investigations before starting methotrexate

Before or at initiation, perform:

Laboratory tests

CBC with differential count and platelet count
AST, ALT, alkaline phosphatase, bilirubin
Albumin
Serum creatinine and estimated GFR
Hepatitis B screening: HBsAg, anti-HBc, and anti-HBs where appropriate
Hepatitis C antibody
HIV testing if risk factors or local protocol indicate
Pregnancy test in women with pregnancy potential

Clinical assessment

Alcohol intake and liver-disease risk assessment
History of chronic liver disease, renal impairment, significant lung disease, immunodeficiency, or recurrent infection
Medication review for interactions
Baseline assessment of cough, dyspnea, and pre-existing interstitial lung disease

Other tests when indicated

Chest radiograph and/or pulmonary evaluation if there is respiratory disease, respiratory symptoms, or concern for underlying lung disease
TB testing is not routinely required for MTX alone, but it is required before most biologic DMARDs and targeted synthetic DMARDs.
Vaccination review before immunosuppression.

7. Laboratory monitoring during methotrexate treatment

Monitor:

CBC with differential and platelets
AST and ALT, with bilirubin and albumin as clinically appropriate
Serum creatinine/eGFR

A practical schedule is:

Period	CBC, LFTs, creatinine/eGFR
Baseline	Before treatment
First 6 weeks or after dose increases	Every 2-4 weeks
Once dose is stable, during first 3 months	Every 4-8 weeks
Long-term stable treatment	Every 8-12 weeks, or every 3-4 months under a stable local protocol

Goldman-Cecil Medicine advises CBC and liver testing monthly during the first 3 months and after dose changes, then every 3-4 months, with renal monitoring because declining GFR decreases MTX clearance. Goldman-Cecil Medicine, p. 2816.

Also assess at every follow-up:

MTX dosing adherence and correct once-weekly use
Adverse effects
Intercurrent infection
Alcohol use
New drugs or over-the-counter medication
Pregnancy plans
RA disease activity and function

8. Role of NSAIDs and whether they prevent progression

NSAIDs provide symptomatic relief of pain, swelling, stiffness, and impaired function while MTX begins to work. Their anti-inflammatory effect comes from cyclooxygenase inhibition and reduced prostaglandin production.

However, NSAIDs:

Do not suppress the autoimmune process sufficiently
Do not prevent erosions or structural joint damage
Do not induce remission
Do not replace a DMARD

Use the lowest effective dose for the shortest duration. Consider gastroprotection with a proton-pump inhibitor if gastrointestinal risk is present. Assess blood pressure, renal function, cardiovascular risk, and gastrointestinal risk.

NSAIDs play little, if any, role in altering the underlying RA disease process and should not be used without a DMARD. Goldman-Cecil Medicine, p. 2795.

9. Options if disease remains active despite an adequate MTX trial

First confirm that the trial was adequate:

Correct once-weekly use and adherence
Adequate folate supplementation
MTX optimized to 20-25 mg weekly if tolerated
Consider change from oral to subcutaneous MTX
Adequate duration, usually at least 3 months for early improvement and about 6 months to achieve the treatment target

If disease remains moderate to high:

Option A: Add another conventional synthetic DMARD

Sulfasalazine
Hydroxychloroquine
Triple therapy: MTX + sulfasalazine + hydroxychloroquine

Option B: Add a biologic DMARD, usually with MTX

Examples:

TNF inhibitors: adalimumab, etanercept, infliximab, certolizumab, golimumab
IL-6 pathway inhibitors: tocilizumab, sarilumab
T-cell costimulation modulator: abatacept
B-cell depleting therapy: rituximab, often considered after TNF inhibitor failure or in selected circumstances

Option C: Add or switch to a targeted synthetic DMARD

JAK inhibitors: tofacitinib, baricitinib, upadacitinib, filgotinib where approved

JAK inhibitors require individualized risk assessment, particularly for age, smoking, cardiovascular disease, venous thromboembolism risk, cancer history, and infection risk.

The treatment goal is remission or low disease activity. If there is no meaningful improvement by 3 months or the target is not achieved by 6 months, treatment should be adjusted (EULAR treatment-to-target guidance).

10. Comparison of DMARD categories

Category	Main examples	Route	Main advantages	Important limitations and safety issues
Conventional synthetic DMARDs	Methotrexate, sulfasalazine, hydroxychloroquine, leflunomide	Oral, MTX also subcutaneous	Established first-line treatment, relatively lower cost, can be combined	Slower onset; MTX, leflunomide, and sulfasalazine need laboratory monitoring
Biologic DMARDs	TNF inhibitors, abatacept, tocilizumab, sarilumab, rituximab	Injection or infusion	Target specific immune pathways; effective after csDMARD failure	Serious infection risk, TB/hepatitis screening, high cost; avoid live vaccines during therapy
Targeted synthetic DMARDs	JAK inhibitors: tofacitinib, baricitinib, upadacitinib, filgotinib	Oral	Target intracellular cytokine signaling; rapid onset; no injections	Infection including herpes zoster, thrombosis, cardiovascular events, malignancy warnings in higher-risk groups; monitor CBC, liver tests, lipids

Key point: MTX is usually retained when a biologic or targeted synthetic DMARD is added, because combination therapy often gives better efficacy and reduces immunogenicity with some biologics.

11. Vaccination and infection precautions with DMARDs

Before or early in DMARD treatment

Review and update vaccines, preferably before major immunosuppression:

Annual inactivated influenza vaccine
COVID-19 vaccination/boosters according to local recommendations
Pneumococcal vaccination
Recombinant zoster vaccine, especially for adults receiving immunosuppressive therapy
Hepatitis B vaccination when risk factors are present
HPV, tetanus, and other age-appropriate routine vaccines

The ACR vaccination guideline recommends pneumococcal vaccination for immunosuppressed rheumatic-disease patients and recombinant zoster vaccination for immunosuppressed adults older than 18 years (ACR vaccination guideline).

Live vaccines

Avoid live attenuated vaccines while receiving significant immunosuppressive therapy, especially biologic DMARDs, JAK inhibitors, and substantial glucocorticoid doses. Examples include live zoster vaccine, MMR, varicella, oral typhoid vaccine, intranasal live influenza vaccine, and yellow fever vaccine.

If a live vaccine is needed, coordinate timing with the rheumatologist before starting therapy or after an appropriate medication interruption.

Influenza vaccination and MTX

For influenza vaccination, temporary holding of MTX for 2 weeks after vaccination can improve vaccine response if RA is stable enough to permit it. This should only be done after rheumatology advice. The ACR guideline specifically supports this approach when disease activity allows (ACR vaccination recommendations).

Infection precautions

Do not start or continue MTX during a serious active infection without prescriber advice.
Seek advice promptly for fever, productive cough, dyspnea, dysuria, shingles, infected wounds, or persistent diarrhea.
Temporarily withhold MTX during significant infections requiring antibiotics or hospitalization, then restart only when clinically recovered and advised by the prescriber.
Screen for TB and hepatitis before biologic or JAK inhibitor treatment.

12. Essential pharmacist counselling

Take MTX once weekly only. Mark a fixed weekly day.
Never take MTX daily for RA. If an extra dose is taken, contact urgent medical services or a poison center immediately.
Take folic acid exactly as prescribed.
Do not stop MTX because it does not give immediate relief. Benefit often begins in 4-6 weeks and may continue to improve over 3-6 months.
Attend all blood-test and rheumatology appointments.
Avoid or strictly minimize alcohol because of liver toxicity risk.
Tell every clinician and pharmacist that she takes weekly MTX.
Avoid self-treatment with interacting drugs, particularly trimethoprim or co-trimoxazole, unless the rheumatology team specifically approves it. These can greatly increase marrow toxicity.
Review NSAID use, antibiotics, proton-pump inhibitors, anticonvulsants, and any herbal medicines with a pharmacist or prescriber.
Use reliable contraception. MTX is teratogenic. Discuss pregnancy planning well in advance with rheumatology and obstetrics.
Do not breastfeed unless a specialist has specifically reviewed the circumstances.
Report mouth ulcers, severe nausea, fever, sore throat, easy bruising, bleeding, jaundice, dark urine, rash, new cough, or shortness of breath promptly.
Do not receive a live vaccine without first discussing it with the rheumatology team.
Maintain exercise, hand exercises, occupational therapy strategies, smoking cessation, and cardiovascular-risk management.

13. Management of significant hepatotoxicity or bone-marrow suppression

If significant hepatotoxicity occurs

Examples include substantial or persistent AST/ALT elevation, jaundice, or clinical hepatitis.

Withhold MTX immediately.
Repeat LFTs and assess severity.
Review alcohol intake, obesity/metabolic risk, viral hepatitis, fatty liver disease, and concomitant hepatotoxic drugs.
Check adherence and confirm that MTX was not mistakenly taken daily.
Do not restart until liver tests normalize or a specialist determines that restarting at a lower dose is appropriate.
If hepatotoxicity is recurrent or severe, discontinue MTX and choose an alternative DMARD.

If marrow suppression occurs

For leukopenia, neutropenia, thrombocytopenia, pancytopenia, or severe mucositis:

Stop MTX immediately.
Urgently repeat CBC, renal function, LFTs, and assess for infection or bleeding.
Evaluate for overdose, renal impairment, interacting drugs, particularly trimethoprim/co-trimoxazole, and folate deficiency.
Severe cytopenia, fever, bleeding, or suspected overdose requires urgent hospital assessment.
Folinic acid (leucovorin) rescue may be required for significant MTX toxicity, under specialist supervision.
Treat neutropenic sepsis, bleeding, or other complications urgently.
Restart only after specialist assessment, usually at a lower dose if the cause is reversible; otherwise use another DMARD.

14. Why glucocorticoids are short-term bridging therapy, not long-term monotherapy

Glucocorticoids such as prednisone work quickly and can reduce pain, swelling, stiffness, and radiographic progression while waiting for MTX to become effective. MTX often requires weeks to months for maximal benefit.

They are not preferred as long-term monotherapy because they do not provide a sustainable disease-modifying strategy with an acceptable long-term risk profile. Long-term glucocorticoids can cause:

Serious infections
Osteoporosis and fractures
Diabetes and weight gain
Hypertension and cardiovascular risk
Cataracts and glaucoma
Skin fragility and poor wound healing
Adrenal suppression
Mood and sleep disturbance
Myopathy

Even low-dose chronic glucocorticoid exposure increases infection risk. Goldman-Cecil Medicine notes extensive long-term toxicity and increased serious-infection risk even at relatively low doses. Goldman-Cecil Medicine, p. 2795.

Use the lowest dose for the shortest duration, with a clear tapering plan. If prolonged therapy is unavoidable, assess bone protection, calcium/vitamin D status, fracture risk, glucose, blood pressure, and infection risk.

3-6 Month Pharmacotherapy Plan

Time point	Treatment plan	Monitoring and safety	Response assessment
Today, baseline	MTX 15 mg orally once weekly. Folic acid 1 mg daily, except on MTX day, or 5 mg the day after MTX. Short course NSAID at lowest effective dose. Consider short tapering oral glucocorticoid only if disease burden is severe.	CBC, platelets, AST/ALT, bilirubin, albumin, creatinine/eGFR, hepatitis B/C testing, pregnancy test, alcohol and drug-interaction review. Update vaccines.	Record tender/swollen joint counts, pain score, function, morning stiffness, ESR/CRP, and DAS28-CRP, CDAI, or SDAI.
2-4 weeks	Continue MTX if tolerated. Manage nausea with bedtime dosing, split same-day dose if advised, antiemetic if needed, or consider subcutaneous route.	CBC, LFTs, creatinine/eGFR. Ask specifically about mouth ulcers, nausea, infection, cough, breathlessness, bruising, alcohol use, and dosing errors.	Confirm correct weekly adherence and early symptom trend.
4-8 weeks	If active disease persists and labs are acceptable, increase MTX by 2.5-5 mg weekly toward 20-25 mg once weekly. Consider subcutaneous MTX if oral intolerance or inadequate response.	Repeat CBC, LFTs, renal function every 2-4 weeks during escalation.	Improvement in swollen and tender joints, function, morning stiffness, ESR/CRP.
12 weeks	Continue optimized MTX if there is meaningful improvement. If inadequate response, verify adherence and dose optimization; consider MTX plus hydroxychloroquine and sulfasalazine, or plan biologic/targeted therapy depending on prognostic factors and local practice.	CBC, LFTs, eGFR. Screen for infection and complete TB/hepatitis screening before biologic/JAK therapy.	There should be clear clinical improvement by this point. If not, reconsider strategy.
24 weeks	Aim for remission or low disease activity. If target is not achieved despite optimized MTX, add a biologic DMARD or a JAK inhibitor after individualized risk assessment, usually while continuing MTX.	Continue laboratory monitoring. Monitor biologic/JAK-specific risks, infection, malignancy and cardiovascular or thrombotic risk when relevant.	Repeat DAS28/CDAI/SDAI, joint examination, ESR/CRP, function, patient-reported pain and fatigue. Consider repeat hand/foot imaging over time to assess structural progression.

Patient-specific target

By 3 months, she should show a clear reduction in swollen joints, stiffness, pain, ESR/CRP, and functional limitation. By 6 months, the desired outcome is remission or low disease activity. If that target is not met, therapy should be escalated rather than leaving her on ineffective treatment.

This is a shared conversation. Sign in to Orris to start your own chat.